Answers are grounded in this paper and cite their sources.
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.).
No takes yet. Share an insight, caveat, or question.
Cao et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: